Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RGNX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Local Steroid | Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2 · NCT04514653 | Active not recruiting |
| Topical Steroid | Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2 · NCT04514653 | Active not recruiting |
| Single intravenous (IV) dose of human Low… | Homozygous Familial Hypercholesterolemia (HoFH) | N/A · NCT04080050 | Unknown |
Also used in these trials (approved or third-party drugs, not RGNX's own candidates): Aflibercept, Ranibizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RGNX had $251M in cash and short-term investments on its Sep 30, 2026 balance sheet. Including the cash events since then, it holds about $290M pro forma, before operating spending after that date:
It burns about $11.8M/quarter from operations, an estimated runway of 73.6 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 54 · Elevated
These conditions raise substantial doubt about the Company's ability to continue as a going concern within 12 months from the date these consolidated financial statements were issued.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RGNX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 7,676,594 | 11.61% | 2026-09-30 |
| Redmile Group, LLC | Institution (13F) | 5,048,502 | 7.64% | 2026-09-30 |
| JPMORGAN CHASE & CO. | Institution (13G, 5%+) | 3,560,915 | 5.39% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 3,153,336 | 4.77% | 2026-09-30 |
| Allan M. Fox Director · +86,415 options |
Insider | 2,911,327 | 4.40% | 2026-05-29 |
| Vanguard Portfolio Management LLC | Institution (13F) | 2,646,375 | 4.00% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 2,522,986 | 3.82% | 2026-09-30 |
| Price (T.Rowe) Associates Inc | Institution (13F) | 1,929,442 | 2.92% | 2026-09-30 |
| Two Sigma Investments, LP | Institution (13F) | 1,899,761 | 2.87% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 1,814,239 | 2.74% | 2026-09-30 |
| Goldman Sachs Group Inc | Institution (13F) | 1,681,187 | 2.54% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 1,582,758 | 2.39% | 2026-09-30 |
Share count 66,122,600 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-01 filed 2026-11-03 |
Christmas Patrick J. |
Award (A) | 34,722 | – | 240,690 |
| 2026-11-01 filed 2026-11-03 |
PAKOLA STEVE |
Award (A) | 34,722 | – | 240,263 |
| 2026-11-01 filed 2026-11-03 |
Chan Mitchell |
Award (A) | 24,305 | – | 147,120 |
| 2026-11-01 filed 2026-11-03 |
Malzahn Craig |
Award (A) | 27,777 | – | 109,737 |
| 2026-09-01 filed 2026-09-03 |
Chan Mitchell |
Tax withholding (F) | 4,902 | $9.32 | 122,815 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-02-08 | RGX-121 | BLA | -32.2% | -0.2% | -22.7% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RGNX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →